Washington, DC 20549





Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported)


March 31, 2020



(Exact name of registrant as specified in its charter)


Delaware   000-51030   59-343-4771

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


150 La Terraza Blvd., Ste 101

Escondido, CA 92025

(Address of principal executive offices, including zip code)


(858) 455-6006

(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Title of each class   Trading Symbol   Name of each exchange on which registered
N/A   N/A   N/A


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).


Emerging growth company [  ]


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]






Item 1.01. Entry Into a Material Definitive Agreement


Amendment to Loan Agreement


On March 31, 2020, TearLab Corporation (the “Company” or “TearLab”) entered into a Consent Agreement (the “Consent”) by and among the Company, certain of its subsidiaries and CRG LP and certain of its affiliate funds as lenders (the “Loan Agreement”). The Consent extends the date on which the principal and interest payments are due under the Loan Agreement from March 31, 2020 to May 31, 2020. Additionally, as of March 31, 2020 the Company was not in compliance with the minimum revenue covenant under the Loan Agreement and the Consent temporarily waives any related default until May 31, 2020. Failure by the Company to make the principal and interest payment on or before May 31, 2020 will result in an immediate event of default under the Loan Agreement.


The foregoing description of the Consent is qualified in its entirety by the terms and conditions of the Consent, the form of which will be attached as an exhibit to the Company’s Quarterly report for the period ending March 31, 2020.






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  By: /s/ Michael Marquez
    Michael Marquez
    Chief Financial Officer


Date: April 6, 2020